Keyword: AstraZeneca

AstraZeneca and Daiichi Sankyo hoped their antibody-drug conjugate could help a tough-to-treat group of breast cancer patients—and the FDA agreed to give it a shot in late December despite a shaky safety profile.

AstraZeneca is testing cotadutide in several clinical trials spanning a range of indications, including heart failure, Type 2 diabetes and kidney failure. Crunching data from one of those trials found that cotadutide reduced liver fat in patients with diabetes who were also overweight or obese.